Ernexa Therapeutics Receives Immediate Nasdaq Delisting Notice, Ineligible for Standard Compliance Period
Summary
Ernexa Therapeutics Inc. received an official delisting notice from Nasdaq for failing to meet the minimum bid price, and is not eligible for the standard compliance period due to a prior reverse stock split.
Key Events
-
Official Delisting Notice Received
On March 18, 2026, Ernexa Therapeutics Inc. received a written notice from Nasdaq for failing to maintain a minimum bid price of $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).
-
Ineligible for Standard Compliance Period
The company is not eligible for the typical 180-calendar day compliance period due to having effected a reverse stock split over the prior one-year period, as per Nasdaq Listing Rule 5810(c)(3)(A)(iv).
-
Company to Request Hearing
Ernexa Therapeutics intends to timely request a hearing before the Nasdaq Hearing Panel, which will automatically stay any suspension or delisting action pending the hearing and any potential extension granted by the Panel.
-
Uncertainty of Continued Listing
There are no assurances that a favorable decision from the Panel will be obtained or that the company's securities will remain listed on The Nasdaq Capital Market.
Analysis
Ernexa Therapeutics Inc. has received an official notice from Nasdaq regarding its failure to maintain the minimum $1.00 bid price. Critically, the company is not eligible for the standard 180-day compliance period because it executed a reverse stock split within the prior year. This significantly accelerates the delisting process, forcing the company to immediately request a hearing with the Nasdaq Hearing Panel. While the request will temporarily stay any delisting action, there are no assurances of a favorable outcome or continued listing. This development escalates the delisting risk previously highlighted in the 10-K filed on March 13, 2026, and poses a severe threat to the company's public market access, especially given its current low stock price.
At the time of this filing, ERNA was trading at $0.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.7M. The 52-week trading range was $0.26 to $4.20. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.